Pier Capital LLC Acquires 128,837 Shares of Capricor Therapeutics, Inc. $CAPR

Pier Capital LLC boosted its holdings in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 35.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 496,554 shares of the biotechnology company’s stock after acquiring an additional 128,837 shares during the quarter. Pier Capital LLC’s holdings in Capricor Therapeutics were worth $3,580,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Farther Finance Advisors LLC purchased a new stake in Capricor Therapeutics in the third quarter worth $28,000. Parkside Financial Bank & Trust purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $36,000. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 2,786 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,976 shares during the period. Finally, Envestnet Asset Management Inc. purchased a new position in Capricor Therapeutics in the 3rd quarter worth about $99,000. Institutional investors own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CAPR. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Capricor Therapeutics in a research report on Wednesday, January 14th. UBS Group set a $50.00 price target on shares of Capricor Therapeutics in a research note on Monday, December 15th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a report on Tuesday. Finally, Oppenheimer increased their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $40.82.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed its review of Capricor’s BLA for Deramiocel and lifted a prior Complete Response Letter, setting a new regulatory timeline — a material positive for approval prospects and valuation. FDA reconsidering Capricor’s snubbed DMD cell therapy after ‘lifting’ rejection
• Positive Sentiment: Late-breaking HOPE-3 Phase 3 data presented at the MDA conference showed significant functional benefits of Deramiocel in Duchenne muscular dystrophy — strengthens the clinical case behind the BLA. Capricor Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference
• Positive Sentiment: Analyst support: HC Wainwright reiterated a Buy rating on CAPR, which can provide continued buy-side interest. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Positive Sentiment: Additional study coverage reported improvements in key heart-function measures for Capricor’s DMD treatment, reinforcing clinical momentum. Capricor Therapeutics’ DMD treatment study shows improvement in key heart function measures
• Neutral Sentiment: Capricor published its fourth-quarter and full-year 2025 financial results and a corporate update; investors will parse cash runway and expense guidance vs. clinical/regulatory milestones. Q4 and Full Year 2025 Financial Results and Corporate Update
• Neutral Sentiment: Pre-earnings/coverage pieces noted that earnings are on deck after the FDA resumed review — these previews can amplify volatility but don’t change fundamentals by themselves. Capricor earnings on deck after FDA resumes deramiocel review
• Neutral Sentiment: Reported short-interest notices show inconsistent/zero data (NaN/0 shares), indicating no reliable short-interest signal from the public filings provided. Investors should treat these short-interest items as data-noise until clarified.
• Negative Sentiment: Capricor missed quarterly EPS estimates (reported a loss of $0.62 vs. consensus -$0.51), which increases near-term earnings disappointment risk and can pressure the stock until revenue/cost outlooks are addressed. Press Release — Quarterly Earnings

Capricor Therapeutics Price Performance

CAPR stock opened at $33.42 on Friday. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37. The business has a 50-day moving average price of $25.66 and a 200 day moving average price of $16.35. The company has a market capitalization of $1.85 billion, a P/E ratio of -18.57 and a beta of 0.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.